- Home
- CRIS vs CALC Comparison
CRIS vs CALC Comparison
Compare CRIS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CALC
- Stock Information
- Founded
- CRIS 2000
- CALC 2011
- Country
- CRIS United States
- CALC United States
- Employees
- CRIS N/A
- CALC N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- CALC Health Care
- Exchange
- CRIS Nasdaq
- CALC Nasdaq
- Market Cap
- CRIS 22.9M
- CALC 48.1M
- IPO Year
- CRIS 2000
- CALC N/A
- Fundamental
- Price
- CRIS $1.71
- CALC $3.12
- Analyst Decision
- CRIS Strong Buy
- CALC Strong Buy
- Analyst Count
- CRIS 2
- CALC 2
- Target Price
- CRIS $16.50
- CALC $14.50
- AVG Volume (30 Days)
- CRIS 74.8K
- CALC 72.1K
- Earning Date
- CRIS 11-13-2025
- CALC 11-12-2025
- Dividend Yield
- CRIS N/A
- CALC N/A
- EPS Growth
- CRIS N/A
- CALC N/A
- EPS
- CRIS N/A
- CALC N/A
- Revenue
- CRIS $11,405,000.00
- CALC N/A
- Revenue This Year
- CRIS $1.41
- CALC N/A
- Revenue Next Year
- CRIS $7.46
- CALC N/A
- P/E Ratio
- CRIS N/A
- CALC N/A
- Revenue Growth
- CRIS 12.24
- CALC N/A
- 52 Week Low
- CRIS $1.02
- CALC $1.42
- 52 Week High
- CRIS $6.44
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- CRIS 48.53
- CALC 52.23
- Support Level
- CRIS $1.63
- CALC $2.62
- Resistance Level
- CRIS $1.95
- CALC $3.73
- Average True Range (ATR)
- CRIS 0.15
- CALC 0.36
- MACD
- CRIS 0.01
- CALC -0.01
- Stochastic Oscillator
- CRIS 29.41
- CALC 44.59
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.